tbuckley/cabot-search huggingface dataset:
Abstract P3-01-13: Comparing portable and clinical ultrasound systems using 3D printed breast phantom inserts
Authors: Dustin Valdez, Jami Fukui, Thomas Wolfgruber, Lambert Leong, Gertraud Maskarinec, John Shepherd
Journal: Cancer Research (2022)

Abstract Background: Late-stage breast cancer rates in the Pacific where mammography services are limited are exceedingly high. Therefore, alternative accessible breast cancer screening technologies such as portable ultrasound is needed. However, little is known about the performance of portable ultrasound when compared to clinical ultrasound for use in breast cancer screening. By utilizing 3D printing technology, it is possible to design breast phantom inserts to replicate various types of lesions. In this study, we utilized 3D printed breast phantom inserts to compare portable and clinical ultrasound lesion detection performance. Methods: Four different breast inserts were designed using FreeCAD (version 0.19) to replicate different lesion detection properties. The first insert compares lesion shape, the second insert investigates depth and size, the third insert looks at fiber diameter, and the fourth insert looks at clusters. The four inserts were printed using a photopolymer resign (Formlabs Inc Rigid resign, Somerville, MA, USA) and then placed in a gelatin-based breast phantom designed for ultrasound use. Using the portable ultrasound (GE Vscan Extend) and clinical ultrasound (Philips EPIQ 5G), various images were captured of identical angle and orientation for both devices. The number of lesions visualized were counted and presented as a percentage of lesions detected. Results: The portable ultrasound had a 100% lesion detection rate for breast insert 1, 90.3% for breast insert 2, 70% for breast insert 3 and 55.8% for breast insert 4. Clinical ultrasound had 100% lesion detection rate for breast insert 1, 93.1% for breast insert 2, 76.6% for breast insert 3, and 99% for breast insert 4. Conclusion: Portable ultrasound shows comparable lesion detection capabilities to clinical ultrasound in 3 of the 4 breast phantom insert tests. Portable ultrasound may have potential as a capable accessible breast cancer screening device in areas without mammography. Citation Format: Dustin Valdez, Jami Fukui, Thomas Wolfgruber, Lambert Leong, Gertraud Maskarinec, John Shepherd. Comparing portable and clinical ultrasound systems using 3D printed breast phantom inserts [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-01-13.
Immunological factors, but not clinical features, predict visceral leishmaniasis relapse in patients co-infected with HIV
Authors: Yegnasew Takele, Tadele Mulaw, Emebet Adem, Caroline Jayne Shaw, Susanne Ursula Franssen, Rebecca Womersley, Myrsini Kaforou, Graham Philip Taylor, Michael Levin, Ingrid Müller, James Anthony Cotton, Pascale Kropf
Journal: Cell Reports Medicine (2021)

Visceral leishmaniasis (VL) has emerged as a clinically important opportunistic infection in HIV patients, as VL/HIV co-infected patients suffer from frequent VL relapse. Here, we follow cohorts of VL patients with or without HIV in Ethiopia. By the end of the study, 78.1% of VL/HIV—but none of the VL patients—experience VL relapse. Despite a clinically defined cure, VL/HIV patients maintain higher parasite loads, lower BMI, hepatosplenomegaly, and pancytopenia. We identify three immunological markers associated with VL relapse in VL/HIV patients: (1) failure to restore antigen-specific production of IFN-γ, (2) persistently lower CD4+ T cell counts, and (3) higher expression of PD1 on CD4+ and CD8+ T cells. We show that these three markers, which can be measured in primary hospital settings in Ethiopia, combine well in predicting VL relapse. The use of our prediction model has the potential to improve disease management and patient care.
LOW FLOW LOW GRADIENT SEVERE AORTIC STENOSIS. IMPACT ON OUTCOMES AFTER TAVR
Authors: George Oikonomou, Chryssavgi Simopoulou, Maria I. Drakopoulou, Padelis Toskas, Anastasios apostolos, Maria Karmpalioti, Andreas G. Synetos, George Latsios, Konstantinos P. Toutouzas
Journal: Journal of the American College of Cardiology (2022)
Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments
Authors: Saife N. Lone, Sabah Nisar, Tariq Masoodi, Mayank Singh, Arshi Rizwan, Sheema Hashem, Wael El-Rifai, Davide Bedognetti, Surinder K. Batra, Mohammad Haris, Ajaz A. Bhat, Muzafar A. Macha
Journal: Molecular Cancer (2022)

Over the past decade, invasive techniques for diagnosing and monitoring cancers are slowly being replaced by non-invasive methods such as liquid biopsy. Liquid biopsies have drastically revolutionized the field of clinical oncology, offering ease in tumor sampling, continuous monitoring by repeated sampling, devising personalized therapeutic regimens, and screening for therapeutic resistance. Liquid biopsies consist of isolating tumor-derived entities like circulating tumor cells, circulating tumor DNA, tumor extracellular vesicles, etc., present in the body fluids of patients with cancer, followed by an analysis of genomic and proteomic data contained within them. Methods for isolation and analysis of liquid biopsies have rapidly evolved over the past few years as described in the review, thus providing greater details about tumor characteristics such as tumor progression, tumor staging, heterogeneity, gene mutations, and clonal evolution, etc. Liquid biopsies from cancer patients have opened up newer avenues in detection and continuous monitoring, treatment based on precision medicine, and screening of markers for therapeutic resistance. Though the technology of liquid biopsies is still evolving, its non-invasive nature promises to open new eras in clinical oncology. The purpose of this review is to provide an overview of the current methodologies involved in liquid biopsies and their application in isolating tumor markers for detection, prognosis, and monitoring cancer treatment outcomes.
ABC-AF STROKE AND BLEEDING SCORES ARE USEFUL TOOLS TO ESTIMATE THE BALANCE BETWEEN BENEFITS AND RISKS WITH DIFFERENT ANTITHROMBOTIC TREATMENTS IN PATIENTS WITH ATRIAL FIBRILLATION: INSIGHTS FROM THE ARISTOTLE AND RE-LY TRIALS
Authors: Ziad Hijazi, Johan Lindbäck, Alexander P. Benz, Jonas Oldgren, Stuart J. Connolly, John W. Eikelboom, John H. Alexander, Renato D. Lopes, Christopher B. Granger, Agneta Siegbahn, Lars Wallentin
Journal: Journal of the American College of Cardiology (2022)
INVESTIGATION OF CARDIAC ARRHYTHMIAS IN CANCER PATIENTS TREATED WITH THORACIC RADIOTHERAPY
Authors: Marwan Refaat, Antoine Bejjani, Wissam Rahi, Chris Kaspar, Bachos Tadros, Farah Abdulhai, Fares Sukhon, Maurice Khoury, Youssef Zeidan, Miran Salame Jaffa
Journal: Journal of the American College of Cardiology (2022)
Diagnostic reasoning: a single entity diagnosis is often inadequate
Authors: William P Whitehouse
Journal: BMJ (2022)

Diagnostic reasoning: a single entity diagnosis is often inadequate William P Whitehouse I enjoyed Brush and colleagues' review of diagnostic reasoning, especially the figures illustrating the relationship between pre-test and post-test probabilities. 1 An educational review should, however, emphasise that a diagnosis is often not a unitary concept such as "aortic dissection", even in cardiology.This is particularly evident in paediatric neurology, where it is important to not just make a diagnosis of the single most likely condition, but to formulate a differential diagnosis as well-for example, when rapidly diagnosing Guillain-Barré syndrome keep the important differentials of acute myelopathy and even botulism in mind, Very occasionally, in a long career, these less likely differentials will prove to be correct.
Concomitant allergic bronchopulmonary aspergillosis and eosinophilic granulomatosis with polyangiitis after Aspergillus niger infection
Authors: I. Alen Coutinho, M. Lopes, F. Lima, C. Ventura, E. Rabadão, T. Alfaro, J.S. da Cunha, F.S. Regateiro
Journal: Pulmonology (2022)
Chemotherapy-Induced Collagen IV Drives Cancer Cell Motility through Activation of Src and Focal Adhesion Kinase
Authors: Jackson P. Fatherree, Justinne R. Guarin, Rachel A. McGinn, Stephen P. Naber, Madeleine J. Oudin
Journal: Cancer Research (2022)

Abstract Triple-negative breast cancer (TNBC) is the most aggressive and deadly subtype of breast cancer, accounting for 30,000 cases annually in the United States. While there are several clinical trials ongoing to identify new agents to treat TNBC, the majority of patients with TNBC are treated with anthracycline- or taxane-based chemotherapies in the neoadjuvant setting, followed by surgical resection and adjuvant chemotherapy. While many patients respond well to this approach, as many as 25% will suffer local or metastatic recurrence within 5 years. Understanding the mechanisms that drive recurrence after chemotherapy treatment is critical to improving survival for patients with TNBC. It is well established that the extracellular matrix (ECM), which provides structure and support to tissues, is a major driver of tumor growth, local invasion, and dissemination of cancer cells to distant metastatic sites. In the present study, we show that decellularized ECM (dECM) obtained from chemotherapy-treated mice increases motility of treatment-naïve breast cancer cells compared with vehicle-treated dECM. Tandem-mass–tag proteomics revealed that anthracycline- and taxane-based chemotherapies induce drug-specific changes in tumor ECM composition. The basement membrane protein collagen IV was significantly upregulated in the ECM of chemotherapy-treated mice and patients treated with neoadjuvant chemotherapy. Collagen IV drove invasion via activation of Src and focal adhesion kinase signaling downstream of integrin α1 and α2, and inhibition of collagen IV–driven signaling decreased motility in chemotherapy-treated dECM. These studies provide a novel mechanism by which chemotherapy may induce metastasis via its effects on ECM composition. Significance: Cytotoxic chemotherapy induces significant changes in the composition of tumor ECM, inducing a more invasive and aggressive phenotype in residual tumor cells following chemotherapy.
INFLUENCE OF INITIAL TREATMENT STRATEGY UPON LATE STATUS AND REINTERVENTION IN NEONATES WITH SYMPTOMATIC TETRALOGY OF FALLOT
Authors: Jeffery Meadows, Andrew C. Glatz, Bryan H. Goldstein, Christopher J. Petit, Courtney McCracken, Mike Kelleman, George T. Nicholson, Mark Aaron Law, Jeffrey Zampi, Shabana Shahanavaz, Christopher E. Mascio, Paul J. Chai, Jennifer C. Romano, Sarosh P. Batlivala, Shiraz Maskatia, Ivor Asztalos, Alicia M. Kamsheh, Steven Healan, Justin Smith, Allen Ligon, Stephan Juergensen, Joelle Pettus
Journal: Journal of the American College of Cardiology (2022)
Treatment of Verruca Plana With Topical Combination of Calcipotriol and Fluorouracil
Authors: Cristina Berumen-Glinz, Fernando de la Barreda-Becerril
Journal: JAMA Dermatology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue
Protective trend of anti-androgen therapy during the COVID-19 pandemic: A meta-analysis
Authors: Jialin Meng, Qintao Ge, Jiawei Li, Xiaofan Lu, Yonghao Chen, Haitao Wang, Meng Zhang, Juan Du, Li Zhang, Zongyao Hao, Chaozhao Liang
Journal: Journal of Infection (2022)
IL-17A mediates pyroptosis via the ERK pathway and contributes to steroid resistance in CRSwNP
Authors: Yue Li, Li-Hong Chang, Wei-Qiang Huang, Hong-Wei Bao, Xia Li, Xiao-Hong Chen, Hao-Tian Wu, Zhou-Zhou Yao, Zi-Zhen Huang, Samuel E. Weinberg, De-Yu Fang, Ya-Na Zhang, Ge-Hua Zhang
Journal: Journal of Allergy and Clinical Immunology (2022)
GENDER DISPARITIES IN SURVIVAL AFTER OUT-OF-HOSPITAL CARDIAC ARREST: AN ANALYSIS FROM THE RESUSCITATION OUTCOMES CONSORTIUM
Authors: Anna Rosenblatt, Ambarish Pandey, Mark S. Link, Ahamed Idris, Robert H. Schmicker, Amgad G. Mentias, Saket Girotra, Purav Mody
Journal: Journal of the American College of Cardiology (2022)
DOES FRAILTY MODULATE HEALTH STATUS IN PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION?
Authors: Padma Kaul, Sarah Rathwell, Carolyn S.P. Lam, Cynthia M. Westerhout, John A. Spertus, Kevin J. Anstrom, Robert Blaustein, Justin A. Ezekowitz, Burkert Mathias Pieske, Lothar Roessig, Javed Butler, Paul Wayne Armstrong
Journal: Journal of the American College of Cardiology (2022)
<i>QuickStats:</i> Rate* of Unintentional Traumatic Brain Injury–Related Deaths† Among Persons Aged ≤19 Years, by Age Group and Sex — National Vital Statistics System, United States, 2018–2020
Journal: MMWR Morbidity and Mortality Weekly Report (2022)

9 10-14 15-19 Deaths per 100,000 population Age group (yrs)Female Male * Deaths per 100,000 population in each age group reported as the average annual rate for 2018-2020, with 95% CIs indicated by error bars.† Based on International Classification of Diseases, Tenth Revision underlying cause-of-death codes V01-X59 or Y85-Y86, and one or more of the following multiple cause-of-death codes: S01.0-S01.9(open wound of head); S02.0, S02.1, S02.3, and S02.7-S02.9(fracture of the skull and facial bones); S04.0 (injury to optic nerve and pathways); S06.0-S06.9(intracranial injury); S07.0, S07.1, S07.8, and S07.9 (crushing injury of head); S09.7-S09.9(other unspecified injuries of head); T01.0 (open wounds involving head with neck); T02.0 (fractures involving head with neck); T04.0 (crushing injuries involving head with neck); T06.0 (injuries of brain and cranial nerves with injuries of nerves and spinal cord at neck level); and T90.1, T90.2, T90.4,T90.5, T90.8, and T90.9 (sequelae of injuries of head).During 2018-2020, death rates for unintentional traumatic brain injury among persons aged ≤19 years were higher for males than for females in each age group.Rates were highest for males (6.1 per 100,000) and females (2.9) among persons aged 15-19 years.Rates were lowest for males and females aged 5-9 years (1.1 and 0.8, respectively) and for males and females aged 10-14 years (1.3 and 0.8, respectively).
Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing
Authors: Alexander Dimitri, Friederike Herbst, Joseph A. Fraietta
Journal: Molecular Cancer (2022)

Abstract Chimeric Antigen Receptor (CAR) T-cells represent a breakthrough in personalized cancer therapy. In this strategy, synthetic receptors comprised of antigen recognition, signaling, and costimulatory domains are used to reprogram T-cells to target tumor cells for destruction. Despite the success of this approach in refractory B-cell malignancies, optimal potency of CAR T-cell therapy for many other cancers, particularly solid tumors, has not been achieved. Factors such as T-cell exhaustion, lack of CAR T-cell persistence, cytokine-related toxicities, and bottlenecks in the manufacturing of autologous products have hampered the safety, effectiveness, and availability of this approach. With the ease and accessibility of CRISPR-Cas9-based gene editing, it is possible to address many of these limitations. Accordingly, current research efforts focus on precision engineering of CAR T-cells with conventional CRISPR-Cas9 systems or novel editors that can install desired genetic changes with or without introduction of a double-stranded break (DSB) into the genome. These tools and strategies can be directly applied to targeting negative regulators of T-cell function, directing therapeutic transgenes to specific genomic loci, and generating reproducibly safe and potent allogeneic universal CAR T-cell products for on-demand cancer immunotherapy. This review evaluates several of the ongoing and future directions of combining next-generation CRISPR-Cas9 gene editing with synthetic biology to optimize CAR T-cell therapy for future clinical trials toward the establishment of a new cancer treatment paradigm.
Standardization of a Developmental Milestone Scale Using Data From Children in Israel
Authors: Tamar Sudry, Deena R. Zimmerman, Hadar Yardeni, Adina Joseph, Ravit Baruch, Itamar Grotto, Dan Greenberg, Roni Eilenberg, Guy Amit, Pinchas Akiva, Meytal Avgil Tsadok, Yitzhak Rize, Hani Zaworbach, Moshe Uziel, Dror Ben Moshe, Irit Lior Sadaka, Eitan Bachmat, Judah Freedman, Yair Sadaka
Journal: JAMA Network Open (2022)

Routine developmental screening tests for children are used worldwide for early detection of developmental delays. However, assessment of developmental milestone norms lacks strong normative data, and there are inconsistencies among different screening tools.To establish milestone norms and build an updated developmental scale.This is a cross-sectional, population-based study conducted between 2014 and 2020. Developmental assessments were conducted by trained public health nurses, documented in national maternal child health clinics, known as Tipat Halav, which serve all children in Israel. Participants included all children born between January 2014 and September 2020, who were followed at the maternal child health clinics from birth to age 6 years. Exclusion criteria were preterm birth, missing gestational age, low birth weight (<2.5 kg), abnormal weight measurement (<3% according to standardized child growth charts), abnormal head circumference measurement (<3% or >97% according to standardized child growth charts), and visits without developmental data or without the child's age. Data analysis was performed from September 2020 to June 2021.In total, 59 milestones in 4 developmental domains were evaluated, and the achievement rate per child's age was calculated for each milestone.A contemporary developmental scale, the Tipat Halav Israel Screening (THIS) Developmental Scale, was built, presenting the 75%, 90%, and 95% achievement rates for each milestone. The THIS scale was compared with other commonly used screening tests, including the Denver Developmental Screening Test II (Denver II), the Alberta Infant Motor Scale (AIMS), and the Centers for Disease Control and Prevention (CDC) Developmental Assessment.A total of 839 574 children were followed in the maternal child health clinics between January 2014 and September 2020 in Israel, and 195 616 children were excluded. A total of 3 774 517 developmental assessments were performed for the remaining 643 958 children aged 0 to 6 years (319 562 female children [49.6%]), resulting in the establishment of new developmental norms. In terms of the comparable milestones, THIS milestones had a match of 18 of 27 (67%) with the Denver II, 7 of 7 (100%) with AIMS, and 10 of 19 (53%) with the CDC Developmental Assessment. The remaining unmatched milestones were achieved earlier in the THIS scale compared with other screening tools.The THIS developmental scale is based on the largest population evaluated to date for developmental performance, representing the heterogeneous, multicultural population comprising this cohort. It is recommended for further evaluation worldwide.
Deconstructing Structural Injustices in the Clinic, Classroom, and Boardroom
Authors: Sundus H. Riaz, Lauren R. Sankary, Timothy E. Brown, Georgina Morley
Journal: The American Journal of Bioethics (2022)

This article is referred to by:The Need for Praxis in Combating the Race Idea in Bioethics: Theory, Reflection, and Action
CARDIAC SARCOIDOSIS MIMICKERS: GENETIC TESTING IN UNDIFFERENTIATED INFLAMMATORY CARDIOMYOPATHIES
Authors: Kolade Agboola, Andrew Rosenbaum, Konstantinos Siontis, John Giudicessi, Omar Farid Abou-Ezzeddine, Naveen L. Pereira
Journal: Journal of the American College of Cardiology (2022)
Science with or without statistics: Discover-generalize-replicate? Discover-replicate-generalize?
Authors: John P.A. Ioannidis
Journal: Behavioral and Brain Sciences (2022)

Overstated generalizability (external validity) is common in research. It may coexist with inflation of the magnitude and statistical support for effects and dismissal of internal validity problems. Generalizability may be secured before attempting replication of proposed discoveries or replication may precede efforts to generalize. These opposite approaches may decrease or increase, respectively, the use of inferential statistics with advantages and disadvantages.
Letter to the editor: vaccination against upper respiratory infections is a matter of survival in alcoholic liver disease
Authors: Timo Itzel, Thomas Falconer, Jimmy Daza, Ana Roig, Jimyung Park, Jae Youn Cheong, Rae Woong Park, Isabella Wiest, Matthias Ebert, George Hripcsak, Andreas Teufel
Journal: Gut (2022)

therefore, be strongly recommended and carried out consistently.
MACHINE LEARNING-BASED PREDICTION OF 1-YEAR ALL-CAUSE MORTALITY IN PATIENTS UNDERGOING VT ABLATION WITH TOPOLOGICAL DATA ANALYSIS
Authors: Ausa Afshar, Klaudia Vivien Nagy, Péter Vámosi, Ferenc Komlósi, Patrik Tóth, Nandor Szegedi, István Osztheimer, Zoltán Salló, Marton Tokodi, Bela Merkely, Laszlo A. Geller
Journal: Journal of the American College of Cardiology (2022)
EPICARDIAL ADIPOSE TISSUE AND CORONARY MICROVASCULAR FUNCTION IN PATIENTS WITH SUSPECTED ANGINA AND NON-OBSTRUCTIVE CORONARY ARTERY
Authors: So Ree Kim, Mi-Na Kim, Hee-Dong Kim, Dong-Hyuk Cho, Sung A Bae, Hack-Lyoung Kim, Myung-A Kim, Wan Joo Shim, Seong-Mi Park
Journal: Journal of the American College of Cardiology (2022)
Abstract ES5-1: Genomic and transcriptomic landscape of TNBC
Authors: Z Shao
Journal: Cancer Research (2022)

Abstract Triple-negative breast cancer (TNBC) is highly heterogeneous. Due to the limited number of TNBCs that have been analyzed, molecular events driving subtypes and prognosis are not firmly established, and little is known regarding TNBC in non-Caucasian patients. Our findings advance the understanding of TNBC subtypes, subdivide the established transcriptome-based subtypes in search of more targeted therapeutic strategies, and offer potential insights to guide subtype-specific therapy. We further conducted a phase Ib/II subtyping-based and genomic biomarker guided umbrella trial to evaluate the efficacy of these targets. Objective response rate (ORR) of these 69 refractory metastatic TNBC patients was 29.0%, while the ORR of arm C (immunotherapy) was 52.6%. Still, genomic and transcriptomic-based target mining do not solve all the problems in TNBC treatment, for example the poor treatment efficacy in luminal androgen receptor (LAR) and basal-like immune-suppressed (BLIS) subtypes. Increasing the dimensions of omics to look for potential therapeutic targets would hopefully solve this problem. Citation Format: Z Shao. Genomic and transcriptomic landscape of TNBC [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr ES5-1.